Pelthos Therapeutics Inc.

AMEX:PTHS

Biotechnology

Healthcare
$16.54 -1.28%

-$0.37 today

Market cap
$63.32M
Beta
3.13
P/E (TTM)
-0.7
EPS (TTM)
-$15.58
52W Low $16.50High $37.50

Volume 0.01M

Average 0.04M

PTHS Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Pelthos Therapeutics Inc.AMEX: PTHS

Retained Earnings · Q1 FY2026 · quarter ended Mar 2026

Retained earnings remains negative

Q1 FY2026 retained earnings was -$75.03M, compared with -$23.44M a year earlier.

Context

  • Retained earnings amounted to 51.6% of total assets at the end of Q1 FY2026, down 2521.2 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -220.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$75.03M-15.8% QoQ
Last fiscal yearDec 2025
-$64.79M-201.7% YoY
Year agoMar 2025
-$23.44M-220.1% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-220.1%——
1 year-201.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(64.79M) USD
Year-over-year change
-201.7%

Retained Earnings vs competitors

How PTHS compares with its peers on the latest reported figures

  • PTHS's Mar 2026 retained earnings of -$75.03M is the 3rd highest of the 4 companies compared; the peer median is -$60M.
  • Its year-over-year change of -220.1% is the lowest of 4, against a peer median of -13.7%.
  • Retained earnings amounts to 51.6% of total assets for PTHS, versus a peer median of 459.1%.
PTHS Competitors Peer median
Retained Earnings for PTHS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ENLVEnlivex Therapeutics Ltd.Dec 2025$1.11B +972.0%—47.6%
LIXTLixte Biotechnology Holdings, Inc.Mar 2026-$60M -13.7%—552.2%
PTHSPelthos Therapeutics Inc.Mar 2026-$75.03M -220.1%—51.6%
CINGCingulate Inc.Mar 2026-$141.69M -26.2%—459.1%
Peer median (excluding PTHS) -$60M-13.7%—459.1%

Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents55.07K96.39K513.44K18.02M
Short-term Investments0000
Net Receivables0040.4K8.86M
Inventory00023.57M
Other Current Assets00750K419K
Total Current Assets55.07K96.39K1.37M52.7M
Property, Plant & Equipment (Net)00012.84M
Goodwill00024.68M
Intangible Assets00039.47M
Long-term Investments0000
Tax Assets0000
Other Non-current Assets000711K
Total Non-current Assets00077.7M
Total Assets55.07K96.39K1.37M130.4M
Account Payables2.99M4.62M1.9M2.99M
Short-term Debt540.43K1.27M2.19M635K
Tax Payables0000
Deferred Revenue000966K
Other Current Liabilities221.88K645.95K021.41M
Total Current Liabilities3.76M6.54M4.08M25.99M
Long-term Debt00031.44M
Deferred Tax Liabilities0000
Deferred Revenue (Non-current)0001.28M
Other Non-current Liabilities00030.05M
Total Non-current Liabilities00065.52M
Total Liabilities3.76M6.54M4.08M91.52M
Common Stock1113916130
Retained Earnings(6.14M)(13.52M)(21.47M)(64.79M)
Accumulated OCI0000
Other Stockholders Equity0000
Minority Interest0000
Total Equity(3.71M)(6.44M)(2.71M)38.88M
Total Debt540.43K1.27M2.19M34.83M
Net Debt485.36K1.17M1.67M16.81M

Pelthos Therapeutics Inc.

AMEX:PTHS

Intrinsic Alpha fair value

Locked

Current Price

$16.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.